Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2026)

Mangoceuticals has disclosed Net Income towards Common Stockholders across 4 years of filings, most recently posting -$3.7 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$3.7 million, up 27.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$20.1 million (down 70.73% YoY), and the FY2025 annual result was -$21.8 million, down 129.47% from the prior year.
• Net Income towards Common Stockholders came in at -$3.7 million for Q1 2026 at Mangoceuticals, down from -$3.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.8 million in Q3 2023 to a low of -$7.9 million in Q3 2025.
• The 4-year median for Net Income towards Common Stockholders is -$2.6 million (2023), against an average of -$3.3 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 245.02% in 2025 and grew 27.98% in 2026, its largest moves.
• Mangoceuticals' Net Income towards Common Stockholders stood at -$2.6 million in 2023, then rose by 24.13% to -$1.9 million in 2024, then slumped by 57.24% to -$3.1 million in 2025, then fell by 20.68% to -$3.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$3.7 million (Q1 2026), -$3.1 million (Q4 2025), and -$7.9 million (Q3 2025), per Business Quant data.